硼中子俘获治疗局部复发头颈部鳞癌的剂量反应与生存分析
该研究纳入79例不可手术的局部复发头颈部鳞癌患者,在芬兰Espoo接受L-硼苯丙氨酸介导的硼中子俘获治疗(BNCT),评估疗效及与治疗反应和生存相关的因素。95%CI 57-79%)有效,2年局部区域无进展生存率38%、总生存率21%;多因素分析显示高肿瘤最小剂量和小体积与长生存独立相关。
要点
- BNCT对局部复发HNSCC有效,可评估患者客观缓解率为68%。
- 高肿瘤最小剂量是治疗反应和生存的预测因素。
- 肿瘤体积小与长生存独立相关。
核心结论
- 多数局部复发头颈部鳞癌患者对BNCT有治疗反应。
- BNCT的高肿瘤最小剂量可预测治疗反应和生存。
研究设计与样本
- 回顾性分析79例不可手术的局部复发头颈部鳞癌患者,2003年2月至2012年1月在芬兰Espoo接受L-硼苯丙氨酸介导的BNCT。
- 既往治疗包括手术和常规分割放疗,中位累积剂量66 Gy(IQR 59-70 Gy),联合或不联合同步化疗。
- 肿瘤反应采用RECIST v1.0标准评估。
主要发现
- 接受2次BNCT的患者反应率高于接受1次者。
- BNCT后中位随访7.8年,2年局部区域无进展生存率38%,总生存率21%。
- 多因素分析显示高肿瘤最小剂量和小体积与长生存独立相关。
关键数值与推荐
- RECIST v1.0标准用于评估肿瘤反应。
- 可评估患者客观缓解率为68%(95%CI 57-79%)。
- 2年局部区域无进展生存率38%,总生存率21%。
临床怎么用
- BNCT可作为不可手术局部复发头颈部鳞癌的治疗选择之一。
- 治疗计划中应关注提高肿瘤最小剂量并考虑肿瘤体积对预后的影响。
局限性
- 原文未报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a therapeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment of such patients and the factors associated with treatment response and survival. METHODS AND MATERIALS: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with l-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012. Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile range [IQR], 59-70 Gy) administered with or without concomitant chemotherapy. Tumor response was assessed using the RECISTv.1.0 criteria. RESULTS: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57-79%) of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable disease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded more often than those treated once. The median follow-up time after BNCT was 7.8 years. The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high minimum tumor dose and a small volume were independently associated with long survival in a multivariable analysis. CONCLUSIONS: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive for response and survival.
引用
- Koivunoro H, Kankaanranta L, Seppälä T, et al. Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival. Radiother Oncol. 2019. PMID: 31108276. doi:10.1016/j.radonc.2019.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。